UPDATE 1-Trinity Biotech's blood-clot analyzer gets FDA nod

* Shares jump 28 pct to 52-week high

July 7 (Reuters) - Medical device maker Trinity Biotech plc (TRIB.O) said U.S. health regulators approved its blood-clot analyzer, Destiny Max, sending its shares soaring 28 percent to a new 52-week high.

The device, already sold in Europe and other international markets, would be launched in the United States with immediate effect, the company said.

Shares of the Ireland-based company were trading up 14 percent at $5.07 in morning trade Tuesday on Nasdaq. They had touched a high of $5.70 earlier in the session. (Reporting by Vidya L Nathan in Bangalore; Editing by Vinu Pilakkott)